This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PPM1D / Protein phosphatase 1D · IHC design guide
Design Immunohistochemistry for PPM1D
Plan PPM1D IHC-P using the reported nuclear and cytoplasmic tissue pattern (HPA tissue IHC). The catalog antibody has a 5 μg/mL IHC starting concentration (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PPM1D Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear and cytoplasmic tissue staining (HPA tissue IHC) | |
| Staining pattern | Nuclear and cytoplasmic staining across several tissues (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Liver staining differs from the reported adult liver absence (HPA tissue IHC; UniProt) | |
| Regulation | Staining-intensity regulation is unreported (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended PPM1D IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with three published PPM1D paraffin-section methods (PMC3610683; PMC4073211; PMC13222862).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A01576); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-PPM1D, 5 μg/mL (datasheet A01576) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PPM1D-positive staining in glandular cells of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: Nuclear and cytoplasmic expression in several different tissue types. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval rule; UniProt O15297: nucleus).
Section 2
What Is the Expected PPM1D Staining Pattern?
PPM1D should show nuclear and cytoplasmic staining in several tissue types by IHC, consistent with its nuclear and cytosolic localization and lack of a transmembrane segment (HPA tissue IHC; UniProt O15297). HPA reports medium staining in kidney tubular cells, liver hepatocytes, and several other listed cell populations (HPA tissue IHC). The tissue IHC assessment is Approved, with external verification pending (HPA tissue IHC).
| Defined nuclear staining, with or without cytoplasmic staining, in kidney tubular cells or liver hepatocytes. | This fits PPM1D's reported nuclear and cytosolic localization and HPA's medium staining in these cell types (UniProt O15297; HPA tissue IHC). Compare the signal with adjacent cells and a counterstain to judge whether it follows cell boundaries and nuclei (general IHC practice). |
| Signal is confined to cell membranes or gland lumens, with no convincing nuclear or cytoplasmic staining. | That distribution is inconsistent with the reported nuclear and cytosolic localization and lack of a transmembrane segment (UniProt O15297). Treat it as a possible staining artefact; inspect tissue morphology and detection controls before assigning PPM1D expression (general IHC practice). |
| Strong staining appears in adipocytes or colon endothelial cells while the expected cell population is unstained. | HPA reports PPM1D as not detected in those specific cell populations, so the result warrants scrutiny; it does not prove absence in every specimen (HPA tissue IHC). Consider antibody cross-reactivity or endogenous chromogenic activity, and compare with an appropriate detection control (general IHC practice). |
| Diffuse colour covers tissue, nuclei, and spaces between cells without a distinct cellular pattern. | A field-wide deposit cannot be scored as the reported nuclear and cytoplasmic pattern (HPA tissue IHC). Assess nonspecific antibody binding, residual endogenous detection activity, and chromogen development with suitable controls; these are general IHC troubleshooting possibilities, not established PPM1D-specific causes (general IHC practice). |
| No specific signal is visible in kidney tubular cells or liver hepatocytes on a test section. | Both are reported at medium staining levels, making them useful comparisons, but their staining is not a guarantee for every specimen or run (HPA tissue IHC). Check section quality, counterstain, controls, retrieval, and antibody dilution before concluding that the test specimen lacks PPM1D (general IHC practice). |
💡Expected PPM1D appearanceA positive IHC result is defined nuclear staining, potentially accompanied by cytoplasmic staining, in reported cells such as kidney tubular cells at HPA's medium level; membrane-only or field-wide colour is suspect (HPA tissue IHC; UniProt O15297; general IHC practice).
| Compartment and cell population | UniProt places PPM1D in the nucleus and cytosol, while HPA reports nuclear and cytoplasmic tissue staining; interpret location together with the stained cell type (UniProt O15297; HPA tissue IHC). HPA's not-detected calls apply to the named cells in the assessed tissues (HPA tissue IHC). |
| Evidence strength across methods | The tissue IHC profile is Approved but pending external verification (HPA tissue IHC). Separately, ICC-IF supports mainly nucleoplasmic localization, with additional nucleolar localization; that finer IF pattern should not be required to recognize a positive chromogenic tissue section (HPA subcellular ICC-IF; HPA tissue IHC). |
| Isoforms and epitope coverage | UniProt lists 2 isoforms and a phosphatase domain at residues 8–375 (UniProt O15297). The supplied record gives no antibody epitope or isoform coverage, so these facts cannot predict which variants the IHC antibody detects or explain a specimen-specific negative result (UniProt O15297; supplied antibody record). |
| Retrieval and processing limits | Antigen retrieval is a general IHC optimization variable, but no PPM1D-specific fixation sensitivity or retrieval outcome is supplied (general IHC practice; supplied evidence). UniProt lists a single 1–605 chain and no signal peptide, propeptide, or transmembrane segment; the record does not support a shedding-based interpretation of staining (UniProt O15297). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected cell populations show no staining. | A failed run, unsuitable retrieval or dilution, or a true low signal are possibilities; none can be distinguished from a blank section alone (general IHC practice). | Review a same-run positive control and section morphology, then optimize retrieval and antibody dilution within the assay instructions before scoring the specimen negative (general IHC practice). Use kidney tubules or hepatocytes as HPA-reported comparisons (HPA tissue IHC). |
| Colour appears mainly on membranes or in lumens. | That pattern conflicts with PPM1D's nuclear and cytosolic localization and lack of a transmembrane segment (UniProt O15297); nonspecific deposition is possible (general IHC practice). | Check the counterstain and cellular boundaries, compare an expected positive population, and inspect detection controls before accepting the signal (general IHC practice; HPA tissue IHC). |
| Adipocytes or colon endothelial cells stain prominently. | HPA reports PPM1D as not detected in those assessed cell populations; cross-reactivity or endogenous chromogenic activity is possible, not established (HPA tissue IHC; general IHC practice). | Compare tissue morphology and an appropriate detection control, then repeat with adjusted blocking or detection conditions if the unexpected signal persists (general IHC practice). |
| The whole section has diffuse chromogenic background. | Nonspecific binding, residual endogenous detection activity, or excessive chromogen development can obscure cellular localization (general IHC practice). | Use the assay's appropriate background controls and review blocking, washes, detection, and development conditions; score only cellular signal distinguishable from background (general IHC practice). |
| Nuclear and cytoplasmic signals differ between tissues. | HPA reports a mixed nuclear and cytoplasmic tissue profile and cell-specific levels, while UniProt reports both nuclear and cytosolic localization (HPA tissue IHC; UniProt O15297). | Record nuclear and cytoplasmic staining separately by cell type and intensity; compare each with the relevant HPA observation instead of imposing one ratio across tissues (HPA tissue IHC; general IHC practice). |
| IF/ICC Q: Should a nucleolar signal be expected in tissue IHC? | HPA's supported ICC-IF observation places PPM1D mainly in nucleoplasm and additionally in nucleoli; tissue IHC is reported more broadly as nuclear and cytoplasmic (HPA subcellular ICC-IF; HPA tissue IHC). | For chromogenic tissue IHC, assess the reported nuclear and cytoplasmic pattern. Treat nucleolar detail as an ICC-IF observation, not a required IHC scoring criterion (HPA subcellular ICC-IF; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing PPM1D staining
A01576 · IHCImmunohistochemistry of PPM1D in human lung carcinoma tissue with PPM1D antibody at 5 μg/ml.
A01576 · IFImmunofluorescence of PPM1D in human lung carcinoma tissue with PPM1D antibody at 20 μg/ml.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000170836-PPM1D/tissue/cerebral+cortex#imid_5837884
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000170836-PPM1D/tissue/colon#imid_5837802
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000170836-PPM1D/tissue/liver#imid_5837803
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000170836-PPM1D/tissue/kidney#imid_5837796
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA061848; green = PPM1D, blue = nucleus, red = microtubules.
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA061848; green = PPM1D, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PPM1D IHC & IF
🧪Run kidney first: tubular cells should show Medium PPM1D staining (HPA: kidney cells in tubules, Medium). Use adipose tissue adipocytes as the negative control (Not detected; HPA: adipose tissue adipocytes); cells without specific staining on the kidney slide should show only background chromogen, with no discrete nuclear signal (HPA subcellular: nucleoplasm supported).
Positive control tissue: Adrenal gland (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PPM1D in Hep-G2, MCF-7, U2OS, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only), a primary-host- and immunoglobulin-class-matched isotype control for a monoclonal antibody (or species-matched nonimmune IgG for a polyclonal antibody), and a PPM1D-knockout biological negative (standard IHC practice). For kidney sections, quench endogenous peroxidase and block endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: The A01576 lung-carcinoma IHC caption reports 5 μg/ml but leaves the fixative unreported; no PPM1D-specific fixation window is supplied (A01576 caption). Antigen-retrieval dependence is unreported, and the supplied evidence does not establish whether frozen sections or IF/ICC are easier; HPA has ICC-IF images in Hep-G2, MCF-7 and U2OS (HPA subcellular). In kidney, endogenous biotin can mimic tubular staining when avidin–biotin detection is used (standard IHC practice).
HPA tissue IHC evidence for PPM1D
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Caudate | Glial cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuropil | Medium | Protein (IHC) | HPA → |
| Kidney | Cells in tubules | Medium | Protein (IHC) | HPA → |
| Liver | Hepatocytes | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Colon | Endothelial cells | Not detected | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced PPM1D IHC Tips
Troubleshoot PPM1D chromogenic IHC in paraffin sections by checking retrieval, compartment, tissue context, and controls before interpreting staining.
What should I change when PPM1D staining is weak after antigen retrieval?
Start with Tris-EDTA pH 9.0 heat-induced epitope retrieval at 95–98 °C for 20 min (page retrieval setting). After cooling, compare the test section with a section processed in the same run that has previously shown staining (standard IHC practice). If staining remains weak, optimize heating time in small increments while keeping antibody concentration and detection conditions constant (standard IHC practice). If that fails, test another retrieval buffer as a fallback on adjacent sections, recording both signal and tissue damage (standard IHC practice). Judge improvement in the expected nuclear and cytoplasmic compartments, rather than by darker staining alone (HPA tissue IHC; UniProt O15297 subcellular location).
Could fixation explain weak or uneven PPM1D staining?
PPM1D-specific sensitivity to fixative type or fixation duration is unknown from the supplied evidence (selected A01576 caption: fixative not stated). Record the fixative and processing history for each paraffin block before comparing staining across specimens (standard IHC practice). For a troubleshooting run, stain adjacent sections together and hold retrieval, antibody incubation, and chromogen development constant (standard IHC practice). Compare well-preserved tissue with regions showing poor morphology; exclude damaged regions from scoring rather than treating their weak signal as biological absence (standard IHC practice). Do not infer fixation tolerance from reported tissue expression or the protein’s lack of a transmembrane segment (HPA tissue IHC; UniProt O15297 topology).
Should PPM1D staining be nuclear, cytoplasmic, or both?
Score nuclear and cytoplasmic signal separately: both compartments are reported for PPM1D in tissue IHC (HPA tissue IHC profile). Predominant nucleoplasmic staining, with additional nucleolar localisation, is supported by cell imaging evidence (HPA subcellular); cytosolic localisation is also annotated (UniProt O15297 subcellular location). Use a counterstain light enough to distinguish nuclear chromogen from dense chromatin, then inspect cytoplasmic boundaries at high magnification (standard IHC practice). Diffuse colour spanning cells and stroma without discernible boundaries should prompt a background and detection review before localisation is assigned (standard IHC practice). Keep separate compartment scores when comparing cases so a shift in distribution does not masquerade as a change in total staining.
Can this stain distinguish PPM1D isoforms or modified epitopes?
The supplied record lists 2 PPM1D isoforms, but gives no antibody epitope or isoform-specific IHC validation (UniProt O15297 isoforms; selected A01576 caption). Therefore, label the result PPM1D immunoreactivity rather than assigning it to isoform 1 or 2. The phosphatase domain spans residues 8–375, and phosphoserines are recorded at residues 40 and 85 (UniProt O15297 domains and modified residues). Those annotations do not establish whether fixation or retrieval masks this antibody’s epitope (UniProt O15297 annotations; selected A01576 caption). To investigate an apparent isoform-specific pattern, obtain the antibody’s epitope information and compare with an independently validated reagent before making that claim (standard IHC validation practice).
How should I adapt this PPM1D assessment for multiplex IF?
Treat multiplex IF as a separate assay: the supplied catalog evidence shows tissue chromogenic staining, while the HPA reports ICC/IF images (selected A01576 caption; HPA subcellular). Pair PPM1D with a validated marker for the expected cell population and choose spectrally separated fluorophores after checking tissue autofluorescence in an unstained section (standard IF practice). PPM1D has no transmembrane segment and has nuclear and cytosolic locations, so intracellular detection calls for a controlled permeabilisation step (UniProt O15297 topology and subcellular location). Titrate permeabilisation against preserved morphology and include single-colour controls to assess bleed-through (standard IF practice). Evaluate nucleoplasmic signal separately from additional nucleolar and cytoplasmic signal (HPA subcellular; UniProt O15297 subcellular location).
How can I reduce diffuse or misleading chromogenic background?
Run a no-primary control alongside each troubleshooting condition to reveal staining from the detection system or tissue itself (standard IHC practice). For peroxidase-based chromogenic IHC, include a peroxidase block before detection and control DAB development time consistently (standard IHC practice). If background persists, compare blocking conditions and antibody concentrations on adjacent sections while keeping retrieval fixed at pH 9.0 (page retrieval setting; standard IHC practice). Inspect folds, torn edges, and necrotic areas separately because staining there can obscure interpretable cell boundaries (standard IHC practice). Accept a changed condition only when cellular nuclear or cytoplasmic signal improves relative to its no-primary control (HPA tissue IHC profile; standard IHC practice).
What is a defensible way to quantify PPM1D IHC? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, because reported PPM1D tissue staining includes nuclear and cytoplasmic expression (HPA tissue IHC profile). Record the percentage of positive cells and staining intensity by compartment; an H-score can summarize the intensity-weighted percentages (standard IHC scoring practice). Normalize counts to the number of evaluable cells in the chosen population, or report positive-cell density per mm² of evaluable tissue (standard image-analysis practice). Apply the same positivity threshold, section selection rules, and chromogen development conditions across specimens (standard IHC practice). Exclude necrosis, folds, and section edges from the denominator, and report nuclear and cytoplasmic results separately.
When is a positive PPM1D stain credible rather than artefactual?
A credible result has identifiable cellular staining in a plausible compartment, with nuclear and cytoplasmic tissue patterns reported for PPM1D (HPA tissue IHC profile). Check the scored cell type: the HPA reports medium staining in kidney tubular cells but no detection in normal lung alveolar cells (HPA tissue IHC). The catalog image documents PPM1D staining in human lung carcinoma at 5 µg/ml; it does not establish the fixative or expected staining of normal alveolar cells (selected A01576 caption). Discount signals concentrated at edges, in necrotic regions, or in the no-primary control, and review peroxidase blocking if chromogen appears independent of primary antibody (standard IHC practice). Interpret a discordant pattern cautiously because the HPA tissue assessment is Approved but pending external verification (HPA tissue IHC reliability).
Boster reagents
Best PPM1D / Protein phosphatase 1D IHC Antibodies
The catalog antibody A01576 has IHC and IF images from human lung carcinoma tissue (catalog image captions) and lists human, mouse, and rat reactivity (catalog: reactivity).
Real IHC data
Anti-Protein phosphatase 1D PPM1D Antibody
Cat # A01576
A01576 will render with an IHC image from human lung carcinoma tissue at 5 μg/mL (catalog: IHC image caption). Its IF image shows human lung carcinoma tissue at 20 μg/mL (catalog: IF image caption).
Which to pick: Choose A01576 for paraffin-section tissue IHC because IHC-P is listed and its own IHC caption shows human lung carcinoma tissue at 5 μg/mL; the fixative is unreported (catalog: applications and IHC image caption). For IF, A01576 has a human tissue image at 20 μg/mL; ICC validation is unreported, and clonality is unspecified (catalog: IF image caption and clone field). A01576 lists mouse and rat reactivity alongside human, but the supplied IHC and IF images show human tissue only (catalog: reactivity and image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O15297 (PPM1D_HUMAN, Protein phosphatase 1D).
- Human Protein Atlas. PPM1D tissue IHC expression (reliability: Approved).
- Human Protein Atlas. PPM1D subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the nucleoli..
- Human Protein Atlas. PPM1D antibody validation summary (2 antibodies).
- Protein phosphatase magnesium-dependent 1δ (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma. PloS one 2013 — PMC3610683.
- PPM1D is a prognostic marker and therapeutic target in colorectal cancer. Experimental and therapeutic medicine 2014 — PMC4079395.
- Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature genetics 2014 — PMC4073211.
- Identification and experimental validation of aging-related biomarkers in intervertebral disc degeneration. Scientific reports 2026 — PMC13222862.
- PubMed PMID:9177166 — UniProt-cited evidence.
- PubMed PMID:16625196 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PPM1D (Protein phosphatase 1D). Expected localisation Nuclear and cytoplasmic tissue staining (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: A01576 at 5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A01576); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-PPM1D, 5 μg/mL (datasheet A01576); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Liver staining differs from the reported adult liver absence (HPA tissue IHC; UniProt); Isoform / epitope: 2 isoforms; epitope coverage is unspecified (UniProt); Regulation: Staining-intensity regulation is unreported (UniProt). Evidence: UniProt O15297, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A01576, PMC3610683, PMC4073211. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PPM1D/immunohistochemistry-ihc-guide.